Österreichischer Sachstandsbericht Klimawandel 2014

The AAR14 is the first Assessment Report on climate Change in Austria assessing the Impact of climate change and the Needs and possibilities of mitigation and Adaptation. This three-volume Report, developed through a multiple peer-Review process including stakeholder participation, presents a coherent assessment of scientific knowledge about climate and makes it accessible for both decision-makers and the General public. Approximately 240 scientists from 50 institutions have participated in this national Assessment ReportDer AAR14 ist der erste Sachstandsbericht zum Klimawandel in Österreich, zu dessen Auswirkungen, und den Erfordernissen und Möglichkeiten der Minderung und Anpassung. Der drei-bändige Bericht, der einen mehrstufigen Peer-Review-Prozess inklusive Stakeholder-Partizipation durchlaufen hat, legt den wissenschaftlich gesicherten Kenntnisstand für Österreich kohärent dar und macht ihn Entscheidungstragenden und der interessierten Öffentlichkeit zugänglich. An dem nationalen Sachstandbericht haben rund 240 WissenschafterInnen aus 50 Institutionen mitgewirkt.Der Österreichische Sachstandsbericht Klimawandel 2014 (AAR14) stellt einen Intergovernmental Panel on Climate Change (IPCC)-ähnlichen Bericht dar. Er besteht aus drei Bänden, in denen das bestehende Wissen zum Klimawandel in Österreich, zu dessen Auswirkungen, und den Erfordernissen und Möglichkeiten der Minderung und Anpassung zusammengefasst wird. Der Bericht verfolgt das Ziel, den wissenschaftlichen Kenntnisstand für Österreich kohärent und vollständig darzulegen und diesen auch in Form von politikrelevanten Analysen an die Österreichische Bundesregierung und politische Entscheidungsgremien auf allen Ebenen zu übermitteln, bzw. um dadurch Entscheidungsgrundlagen auch für den privaten Sektor und einen Wissensfundus für akademische Institutionen bereitzustellen. Ähnlich den IPCC-Sachstandsberichten liegt dem AAR14 das Prinzip zugrunde, entscheidungsrelevant zu sein, aber keinen empfehlenden Charakter zu haben

Österreichischer Sachstandsbericht Klimawandel 2014

The AAR14 is the first Assessment Report on climate Change in Austria assessing the Impact of climate change and the Needs and possibilities of mitigation and Adaptation. This three-volume Report, developed through a multiple peer-Review process including stakeholder participation, presents a coherent assessment of scientific knowledge about climate and makes it accessible for both decision-makers and the General public. Approximately 240 scientists from 50 institutions have participated in this national Assessment Repor

PIConGPU setup: Gas-foil target for ion acceleration

This data set contains the PIConGPU source code used for the simulations presented in "Gas-foil target for ion acceleration" and the setup files

Dendritic cells facilitate accumulation of il-17t cells in the kidney following acute renal obstruction

Acute urinary obstruction causes interstitial inflammation with leukocyte accumulation and the secretion of soluble mediators. Here we show that unilateral ureteral ligation caused a progressive increase in renal F4/80(+) and F4/80(-) dendritic cells, monocytes, neutrophils and T-cells 24-72 h following obstruction. Depletion of dendritic cells by clodronate pretreatment showed these cells to be the most potent source of tumor necrosis factor and other pro-inflammatory mediators in the obstructed kidney. F4/80(+) dendritic cells and T-cells co-localized in the cortico-medullary junction and cortex of the obstructed kidney. Cytokine secretion patterns and surface phenotypes of T-cells from obstructed kidneys were found to include interferon-gamma-secreting CD4(+) and CD8(+) memory T-cells as well as interleukin 17 (IL-17)-secreting CD4(+) memory T-cells. Depletion of the intra-renal dendritic cells prior to ligation did not numerically reduce T-cells in obstructed kidneys but attenuated interferon-gamma and IL-17-competent T-cells. Our study shows that intra-renal dendritic cells are a previously unidentified early source of proinflammatory mediators after acute urinary obstruction and play a specific role in recruitment and activation of effector-memory T-cells including IL-17-secreting CD4(+) T-cells

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

Standard first-line treatment of aggressive B cell lymphoma comprises six or eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus eight doses of rituximab (R). Whether adding two doses of rituximab to six cycles of R-CHOP is of therapeutic benefit has not been systematically investigated. The Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial investigated the ability of [F-18]-fluorodesoxyglucose PET scanning to guide treatment in aggressive non-Hodgkin lymphomas. Patients with B cell lymphomas and a negative interim scan received six cycles of R-CHOP with or without two extra doses of rituximab. For reasons related to trial design, only about a third underwent randomization between the two options. Combining randomized and non-randomized patients enabled subgroup analyses for diffuse large B cell lymphoma (DLBCL; n=544), primary mediastinal B cell lymphoma (PMBCL; n=37), and follicular lymphoma (FL) grade 3 (n=35). With a median follow-up of 52months, increasing the number of rituximab administrations failed to improve outcome. A non-significant trend for improved event-free survival was seen in DLBCL high-risk patients, as defined by the International Prognostic Index, while inferior survival was observed in female patients below the age of 60years. Long-term outcome in PMBCL was excellent. Differences between FL grade 3a and FL grade 3b were not apparent. The results were confirmed in a Cox proportional hazard regression model and a propensity score matching analysis. In conclusion, adding two doses of rituximab to six cycles of R-CHOP did not improve outcome in patients with aggressive B cell lymphomas and a fast metabolic treatment response